COVID-19 and anticoagulation: evidence from a meta-analysis of randomized controlled trials.
作者信息
Zhou Yanan, Yang Yanping, Wang Ying, Hou Dongni, Song Yuanlin
机构信息
Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.
Shanghai Key Laboratory of Lung Inflammation and Injury, Shanghai Respiratory Research Institute, Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
出版信息
J Thorac Dis. 2025 Apr 30;17(4):2741-2743. doi: 10.21037/jtd-2025-407. Epub 2025 Apr 18.
Abstract
摘要
相似文献
1
COVID-19 and anticoagulation: evidence from a meta-analysis of randomized controlled trials.
J Thorac Dis. 2025 Apr 30;17(4):2741-2743. doi: 10.21037/jtd-2025-407. Epub 2025 Apr 18.
2
The effect of higher-intensity dosing of anticoagulation on the clinical outcomes in hospitalized patients with COVID-19: A meta-analysis of randomized controlled trials.
J Infect Chemother. 2022 Feb;28(2):257-265. doi: 10.1016/j.jiac.2021.11.008. Epub 2021 Nov 17.
3
Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials.
J Thromb Thrombolysis. 2022 Oct;54(3):420-430. doi: 10.1007/s11239-022-02681-x. Epub 2022 Aug 3.
4
Anticoagulation therapy in hospitalized patients with COVID-19: a meta-analysis of randomized clinical trials.
Bratisl Lek Listy. 2023;124(11):848-855. doi: 10.4149/BLL_2023_131.
5
Optimal dosing of heparin for prophylactic anticoagulation in critically ill COVID-19 patients a systematic review and meta-analysis of randomized controlled trials.
J Crit Care. 2023 Oct;77:154344. doi: 10.1016/j.jcrc.2023.154344. Epub 2023 May 25.
6
Therapeutic-dose anticoagulation or thromboprophylaxis with low-molecular-weight heparin for moderate Covid-19: meta-analysis of randomized controlled trials.
Clin Exp Med. 2023 Aug;23(4):1189-1196. doi: 10.1007/s10238-022-00876-3. Epub 2022 Sep 1.
7
Safety and efficacy of prophylactic anticoagulation versus therapeutic anticoagulation in hospital-admitted COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials.
Clin Respir J. 2023 Feb;17(2):73-79. doi: 10.1111/crj.13568. Epub 2022 Dec 26.
8
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.
Eur Heart J Cardiovasc Pharmacother. 2022 Sep 29;8(7):677-686. doi: 10.1093/ehjcvp/pvab070.
9
Oral anticoagulation versus antiplatelet or placebo for stroke prevention in patients with heart failure and sinus rhythm: Systematic review and meta-analysis of randomized controlled trials.
Int J Stroke. 2019 Dec;14(9):856-861. doi: 10.1177/1747493019877296. Epub 2019 Sep 16.
10
Anticoagulation in COVID-19 patients - An updated systematic review and meta-analysis.
Thromb Res. 2024 Jun;238:141-150. doi: 10.1016/j.thromres.2024.04.007. Epub 2024 May 1.
本文引用的文献
1
Anticoagulant therapy in adult with COVID-19: a systematic review and meta-analysis of randomized controlled trial.
J Thorac Dis. 2024 Oct 31;16(10):6391-6405. doi: 10.21037/jtd-24-744. Epub 2024 Oct 17.
2
Inhaled nebulised unfractionated heparin (UFH) for the treatment of hospitalised patients with COVID-19: A randomised controlled pilot study.
Pulm Pharmacol Ther. 2023 Jun;80:102212. doi: 10.1016/j.pupt.2023.102212. Epub 2023 Mar 27.
3
Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial.
JAMA. 2021 Nov 2;326(17):1703-1712. doi: 10.1001/jama.2021.17272.
4
Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.
Lancet Respir Med. 2021 Apr;9(4):360-372. doi: 10.1016/S2213-2600(20)30470-7. Epub 2021 Jan 22.
5
Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence.
Crit Care. 2020 Jul 22;24(1):454. doi: 10.1186/s13054-020-03148-2.
6
A phase 1 trial of nebulised heparin in acute lung injury.
Crit Care. 2008;12(3):R64. doi: 10.1186/cc6894. Epub 2008 May 6.
Zotero 插件